4.7 Article

SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia

Journal

BLOOD
Volume 121, Issue 1, Pages 148-155

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2012-05-428938

Keywords

-

Categories

Funding

  1. ECOG leukemia tissue bank
  2. National Institutes of Health(NIH)/National Cancer Institute (NCI) [R01CA137060, R01CA139032, R01CA157644, R01CA169458, R21CA152497]
  3. NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) [R01AR54153]
  4. Leukemia & Lymphoma Society [6132-09, 6097-10, 6221-12, 7005-11]
  5. William Lawrence and Blanche Hughes Foundation and a Stand Up To Cancer-American Association for Cancer Research Innovative Research Grant [IRG00909]
  6. California Institute for Regenerative Medicine (CIRM) [TR2-01 816]

Ask authors/readers for more resources

The Sox4 transcription factor mediates early B-cell differentiation. Compared with normal pre-B cells, SOX4 promoter regions in Ph+ ALL cells are significantly hypomethylated. Loss and gain-of-function experiments identified Sox4 as a critical activator of PI3K/AKT and MAPK signaling in ALL cells. ChIP experiments confirmed that SOX4 binds to and transcriptionally activates promoters of multiple components within the PI3K/AKT and MAPK signaling pathways. Cre-mediated deletion of Sox4 had little effect on normal pre-B cells but compromised proliferation and viability of leukemia cells, which was rescued by BCL2L1 and constitutively active AKT and p110 PI3K. Consistent with these findings, high levels of SOX4 expression in ALL cells at the time of diagnosis predicted poor outcome in a pediatric clinical trial (COG P9906). Collectively, these studies identify SOX4 as a central mediator of oncogenic PI3K/AKT and MAPK signaling in ALL. (Blood. 2013; 121(1): 148-155)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available